True North Labs

Author: labstruenorth@gmail.com

  • Peptide and Nanobody Drug Conjugates Gain Momentum as Targeted Therapy Platforms

    Drug conjugates—molecules that pair a targeting component with a therapeutic payload—have long been dominated by antibody-drug conjugates (ADCs), which use full-sized antibodies to guide cytotoxic agents to cancer cells. Recent industry coverage points to a rapid expansion of a related but distinct approach: conjugates built on peptides and nanobodies, smaller molecular scaffolds that can offer some advantages over conventional antibodies while introducing their own design considerations.

    Peptides are short chains of amino acids that can be engineered to bind selectively to receptors or proteins found on particular cell types. Nanobodies, derived from the single-domain antibody fragments found in camelid species such as llamas and alpacas, retain antigen-binding capability but are a fraction of the size of standard antibodies. Because both formats are smaller and structurally simpler than full antibodies, they can potentially penetrate tissues more readily, be manufactured through more straightforward chemical or biological processes, and be engineered with greater flexibility in how a payload is attached.

    These properties have made peptide and nanobody conjugates attractive across a range of applications, including oncology, imaging, and other disease areas where precise delivery of a drug or diagnostic agent to a specific tissue is important. Proponents of the approach suggest that smaller targeting molecules may reduce certain manufacturing complexities associated with large antibody proteins, while still allowing for conjugation to cytotoxic drugs, radioisotopes, or other therapeutic payloads. At the same time, smaller scaffolds can face their own hurdles, such as shorter circulation times in the body, which developers address through chemical modifications or formulation strategies.

    The reported growth in this space suggests increasing interest from biotechnology and pharmaceutical developers in diversifying the toolkit used for targeted therapies beyond traditional ADCs. As with any emerging drug class, peptide and nanobody conjugates must still progress through preclinical evaluation and clinical trials to establish safety and efficacy before they can be considered for broader use. Researchers continue to study how factors like binding affinity, linker chemistry, and payload selection influence performance, and regulatory pathways for these newer conjugate formats are still being clarified as more candidates advance through development.

    Overall, the expansion of peptide and nanobody drug conjugates illustrates a broader trend in pharmaceutical research: the search for targeting platforms that balance precision, manufacturability, and adaptability. Whether these approaches will match or complement the clinical track record established by antibody-drug conjugates remains an active area of investigation as more candidates move through trials. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only — not medical advice.

    Source: Rapid Expansion Of Peptide And Nanobody Drug Conjugates – Clinical Leader

  • FDA Advisory Panel Recommends BPC-157 for Compounding Pharmacy List

    An advisory committee to the U.S. Food and Drug Administration has voted in favor of adding BPC-157 to a federal list of substances that compounding pharmacies may use when preparing customized medications. The vote comes amid growing public interest in the peptide, which has circulated widely in research forums, athletic communities, and online wellness discussions, often accompanied by anecdotal claims about tissue repair and recovery.

    To understand why this matters, it helps to know how compounding works. Compounding pharmacies prepare individualized medications for patients, often when a commercially manufactured drug doesn’t meet a specific need—such as a different dosage, form, or combination of ingredients. The FDA maintains lists of substances, sometimes called the 503A and 503B lists, that determine which bulk drug substances compounders are permitted to use. Getting added to these lists is a regulatory pathway distinct from full FDA drug approval, which requires extensive clinical trials demonstrating safety and effectiveness for a specific indication.

    BPC-157 is a synthetic peptide derived from a protein fragment originally identified in gastric juice. It has been studied in preclinical research, primarily in animal models, exploring potential effects on gut lining, tendon and ligament healing, and inflammation. However, it has not undergone the large-scale, controlled human clinical trials that the FDA typically requires before approving a substance as a prescription drug for a specific medical use. Currently, BPC-157 is not an FDA-approved drug, and it has appeared on the agency’s list of bulk substances that present significant safety concerns for compounding, which limits how compounders can legally offer it.

    A recommendation from an advisory committee is not the same as final agency action. Advisory committees, typically composed of outside experts, review available evidence and provide non-binding recommendations to the FDA, which retains ultimate authority over whether to accept, modify, or reject such advice. If the FDA does move to add BPC-157 to a permitted compounding list, it would still likely come with conditions—such as restrictions on specific formulations, dosing, or labeling—rather than a blanket clearance for unrestricted use. The regulatory process for compounded substances also differs from, and is generally less rigorous than, the pathway for a fully approved prescription drug.

    Interest in peptides like BPC-157 has grown alongside broader consumer curiosity about compounded and research-use compounds, but oversight of these products remains a developing and sometimes contested area of pharmaceutical regulation. Observers who follow FDA compounding policy will likely watch for further agency statements clarifying what any change in listing status would mean in practice for pharmacies, prescribers, and consumers.

    This article is for informational purposes only and is not intended as medical advice. Readers with questions about specific substances or health decisions should consult a qualified healthcare professional.

    Curated by True North Labs. More at truenorthlabs.co. Informational only — not medical advice.

    Source: FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list – ABC News – Breaking News, Latest News and Videos